
2019

I01 Nurul Azrin Abd Rahman A population pharmacokinetic/pharmacodynamic (PK/PD) model of the investigational antimalarial drug Artefenomel in a Plasmodium vivax VolunteerInfection Study Wednesday 09:5011:15 
I02 Mahmoud Abdelwahab Clofazimine population pharmacokinetics in South African patients with drug resistant tuberculosis Wednesday 09:5011:15 
I03 Khaled Abduljalil Integrating a tumour Growth inhibition Model within a PhysiologicallyBased Pharmacokinetic Model to predict Erlotinib tumour concentrations in Mice Wednesday 09:5011:15 
I04 Anson Abraham Lack of preclinical target pharmacology: How to predict firstinhuman trial dose(s) and inform clinical trial design? Wednesday 09:5011:15 
I05 Ahmad Abuhelwa Population pharmacokinetic and pharmacodynamic modelling of the therapeutic and adverse effects of ketamine in patients with treatmentrefractory depression Wednesday 09:5011:15 
I06 Ahmed Aliyu Abulfathi External validation of a paraaminosalicylic acid population pharmacokinetics model using the ncappc R package Wednesday 09:5011:15 
I07 Oliver Ackaert Characterizing exposure of apalutamide and its active metabolite, Ndesmethylapalutamide, in healthy and castrationresistant prostate cancer subjects Wednesday 09:5011:15 
I08 Bambang Adiwijaya Component score models of HAMD were more predictive than total score models Wednesday 09:5011:15 
I09 Jae Eun Ahn Longitudinal ModelBased MetaAnalysis for Liver Biomarkers and Biopsy Endpoints in Patients with NonAlcoholic Fatty Liver Disease Wednesday 09:5011:15 
I10 Maurice Ahsman A mechanismbased population KPD model for longterm testosterone inhibition in prostate cancer patients under intermittent androgen deprivation therapy Wednesday 09:5011:15 
I11 Marie Alexandre Modeling viral rebound in HIV therapeutic vaccine studies Wednesday 09:5011:15 
I12 Joachim Almquist Estimation of equipotent doses of the oral selective glucocorticoid receptor modulator (oSGRM) AZD9567 and prednisolone based on ex vivo TNFa inhibition after LPS stimulation Wednesday 09:5011:15 
I13 Jokha ALQassabi Predicting the Fraction Unbound (fu) and Plasma Drug Clearance Based on Known Changes in Albumin and Alpha1Acid Glycoprotein Levels at Varying Degrees of Renal Impairment Wednesday 09:5011:15 
I14 Hesham AlSallami The use of a Bayesian dosing tool to optimise enoxaparin treatment: a pilot clinical study Wednesday 09:5011:15 
I15 Vincent AranzanaCliment Use of a semimechanistic PKPD model to quantify the combination effect of polymyxin B and minocycline against polymyxinresistant Acinetobacter baumannii Wednesday 09:5011:15 
I16 Million Arefayene Population Pharmacokinetics (PK) and pharmacodynamics (PD) Modeling of antiavß6 integrin Antibody (BG00011) Wednesday 09:5011:15 
I17 Leticia Arrington An R package for Automated Generation of Item Response Theory Model NONMEM Control File Wednesday 09:5011:15 
I18 Usman Arshad A semimechanistic pharmacokineticpharmacodynamic model of 5fluorouracil continuous infusion in gastrointestinal cancer patients Wednesday 09:5011:15 
I19 Muhammad Waqar Ashraf Mechanistic model to characterize the pharmacokinetics and dynamics of subcutaneous dexmedetomidine in healthy adult volunteers Wednesday 09:5011:15 
I20 Magnus Åstrand nonmem2R: An Rpackage for Visual Predictive Checks and Goodnessoffit Plots Wednesday 09:5011:15 
I21 Ioanna Athanasiadou Hyperhydration effect on pharmacokinetic parameters of recombinant human erythropoietin in urine and serum doping control analysis Wednesday 09:5011:15 
I22 Linda Aulin Physiologicallybased pharmacokinetic model to predict lung distribution of antiinfective agents Wednesday 09:5011:15 
I23 Ahmad Rami Ayoun Alsoud Simultaneous Assessment of Timetopositivity and Colonyforming Unit in tuberculosis patients under highdose rifampicin therapy Wednesday 09:5011:15 
I24 Geraldine Ayral Straightforward dose adaptation simulations with Simulx, the simulator of the MonolixSuite Wednesday 09:5011:15 
I25 LE Ba Hai Population pharmacokinetic model of sorafenib and application to a case report Wednesday 09:5011:15 
I26 Junjie Ding Pharmacometric drug adherence approach and its application in a clinical setting Wednesday 09:5011:15 
I27 Vanessa Baier Assessing the cholestatic potential of drugs using a physiologybased model of the bile acid metabolism Wednesday 09:5011:15 
I28 Pavel Balazki A mechanistic model of gastric emptying of caloric liquids and solids for the use in physiologicallybased pharmacokinetics models. Wednesday 09:5011:15 
I29 Violeta BalbasMartinez Quantitative Systems Pharmacology model for the key Interleukins involved in Crohn's Disease Wednesday 09:5011:15 
I30 Irina Baltcheva ggPMX: an opensource R package for pharmacometric model diagnostic plots Wednesday 09:5011:15 
I31 Maddlie Bardol Population pharmacokinetics of fentanyl in very preterm infants Wednesday 09:5011:15 
I32 Christian Bartels Getting a better description of treatment effects for time to event data using PKPD modelling Wednesday 09:5011:15 
I33 Roberta Bartolucci Optimal design of paediatric clinical trials: the Macitentan case study Wednesday 09:5011:15 
I34 Carla Bastida Fernández Assessment of tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients Wednesday 09:5011:15 
I35 Francesco Bellanti Application of ModelBased MetaAnalysis to evaluate the relationship between early biomarker to late stage clinical endpoints for the development of antiasthmatic drugs Wednesday 09:5011:15 
I36 Amina Bensalem Nonlinear pharmacokinetics and concentrationeffect relationship of rituximab in antineutrophil cytoplasmic antibody associated vasculitis Wednesday 09:5011:15 
I37 Linnea Bergenholm Predicting plasma and liver exposure in humans with a pharmacokinetic model for a GalNAc3conjugated antisense oligonucleotide using sparse monkey data Wednesday 09:5011:15 
I38 Aliénor Bergès Importance of Quantifying Neutropenia Risk Factors in Phase I Solid Malignancy Dose Finding; A Simulation Case Wednesday 09:5011:15 
I39 Martin Bergstrand Caplacizumab Dosing Rational in aTTP Patients Supported by Mechanism Based PKPD Modelling Wednesday 09:5011:15 
I40 Jan Berkhout Application of population PK/PD modeling and simulation to inform the design of a dosefinding study in patients with schizophrenia Wednesday 09:5011:15 
I41 Julie Bertrand Modelbased approach for group sequential and adaptive designs in parallel and crossover bioequivalence studies Wednesday 09:5011:15 
I42 Robert Bies On the Multilemma of reproducibility: Stochastic or Deterministic or Stochastic and Deterministic Wednesday 09:5011:15 
I43 Bruno Bieth Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in NonSmall Cell Lung Cancer Wednesday 09:5011:15 
I44 Roberto Bizzotto Conditional linear mixedeffect modelling of HbA1c and fasting glucose in diabetic patients shows that progression rates for the two variables are different: an IMI DIRECT study Wednesday 09:5011:15 
I45 Irina Bondareva Population pharmacokinetics of levetiracetam (LEV) in preterm neonates with seizures based on sparse therapeutic drug monitoring (TDM) data Wednesday 09:5011:15 
I46 Guillaume Bonnefois A new computational approach to match control subjects to renal impaired patients in pharmacokinetic studies Wednesday 09:5011:15 
I47 Elisa Borella Development of a TargetMediated Drug Disposition Model for the Prediction of Target Occupancy of MEN1112, an Anti Bst1/CD157 Humanized Antibody for the Treatment of Acute Myeloid Leukaemia Wednesday 09:5011:15 
I48 Agnieszka BorsukDe Moor The influence of age and body weight on pharmacokinetics and pharmacodynamics of dexmedetomidine in rabbits Wednesday 09:5011:15 
I49 Thomas Bouillon Model predictive control with Bayesian updates (MPC) is more robust to model misspecification, compared to standard Bayesian control (sEBE) for Therapeutic Drug Management (TDM). Investigation in a cohort of 315 patients receiving tacrolimus during the first 14d after renal transplantation. Wednesday 09:5011:15 
I50 Marion BouillonPichault Modelbased metaanalysis of efficacy and safety of antiPD1 compounds in melanoma Wednesday 09:5011:15 
I51 Muriel Boulton What is the proportion of abiraterone acetate effect on radiographic ProgressionFreeSurvival (rPFS) explained by Prostate‐Specific Antigen (PSA) kinetics in metastatic castrationresistant prostate cancer (mCRPC)? Wednesday 09:5011:15 
I52 Ari Brekkan Viggosson Model based support to biosimilarity assessment planning – A case study of pegfilgrastim Wednesday 09:5011:15 
I53 Astrid Broeker Parameter uncertainty in small datasets – evaluation approaches at their limit Wednesday 09:5011:15 
I54 Vincent Buchheit Data scientists for improving efficiency and quality of quantitative clinical pharmacology analyses Wednesday 09:5011:15 
I55 Núria Buil Bruna Can monocyte counts predict future druginduced neutropenia toxicities? Wednesday 09:5011:15 
I56 David Busse Analysis of targetsite distribution of meropenem in morbidly obese and nonobese patients using nonlinear mixedeffects modelling Wednesday 09:5011:15 
I57 Antonio Cabal Using multiscale mechanism based mathematical modeling to address many of the challenges associated with the estimation of local lung concentration after inhaled drug delivery Wednesday 09:5011:15 
I58 Unai Caballero Pharmacodynamic modelling to evaluate the in vitro activity of amphotericin B against Candida auris Wednesday 09:5011:15 
I59 Elisa Calvier Alirocumab population pharmacokinetics in Chinese patients using priors Wednesday 09:5011:15 
I60 Tim Cardilin Tumor Static Exposure for anticancer combinations in early drug discovery Wednesday 09:5011:15 
I61 Fernando Carreño Population Pharmacokinetic Modeling of Quetiapine Lipid Core Nanocapsules in a Neurodevelopmental Animal Model of Schizophrenia Wednesday 09:5011:15 
I62 Jantine Brussee Modelbased dose optimization of ivermectin to achieve equivalent exposure coverage in children and adults Wednesday 09:5011:15 
I63 Blesson Chacko Why patients may not benefit from effective oncology drugs Wednesday 09:5011:15 
I64 Dong Woo Chae Predictive model of postoperative nausea and vomiting in patients treated with Fentanylbased intravenous patient controlled analgesia Wednesday 09:5011:15 
I65 Anne Chain A Model Based MetaAnalysis of second generation antipsychotics for the treatment of Schizophrenia Wednesday 09:5011:15 
I66 Anna Chan Kwong Bridging studies: handling covariates models using the Prior approach Wednesday 09:5011:15 
I67 Christophe Chassagnole A precision dosing application for docetaxel in metastatic prostate cancer Wednesday 09:5011:15 
I68 Estelle Chasseloup Use of mixture models in pharmacometric modelbased analysis of confirmatory trials: part II – control of the type I error with real placebo data Wednesday 09:5011:15 
I69 Jonathan Chauvin Novel userfriendly applications for dose individualization of sunitinib and imatinib Wednesday 09:5011:15 
I70 Alexia Chauzy Semimechanistic pharmacodynamics modeling of aztreonamavibactam combination to understand its antimicrobial activity against multidrugresistant Gramnegative bacteria Wednesday 09:5011:15 
I71 Viji Chelliah Mechanistic models of cancerimmune cycle and immunotherapies Wednesday 09:5011:15 
I72 Lu Chen Bioavailability and the Variability of Posaconazole Exposure in Healthy Volunteers Using a Population Pharmacokinetic Analysis Wednesday 09:5011:15 
I73 Maxwell Tawanda Chirehwa Population pharmacokinetics of cycloserine dosed as terizidone in drugresistant tuberculosis patients Wednesday 09:5011:15 
I74 Siri Kalyan Chirumamilla Application of physiologicallybased pharmacokinetic model to mechanistically predict increased tumour uptake of paclitaxel in cancer patients Wednesday 09:5011:15 
I75 Palang Chotsiri Mechanistic modelling of primaquine pharmacokinetics, gametocyte clearance, and mosquito infectivity Wednesday 09:5011:15 
I76 Emmanuelle Comets Conditional nonparametric bootstrap for nonlinear mixed effect models Wednesday 09:5011:15 
I77 Valerie Cosson Targetmediated drug disposition model of RG6206 (RO7239361), an antimyostatin adnectinIgG1Fcfusion protein, with positive feedback on myostatin endogenous production in healthy adults but not in boys with Duchenne Muscular Dystrophy Wednesday 09:5011:15 
I78 Perrine Courlet Influence of drugdrug interactions on population pharmacokinetics of atorvastatin and its active metabolite orthoOHatorvastatin in people living with HIV. Wednesday 09:5011:15 
I79 Sinziana Cristea Untangling maturation functions for kidney transporters using a combined population pharmacokinetics and physiologybased pharmacokinetics approach Wednesday 09:5011:15 
I80 Salvatore D'Agate Population Pharmacokinetics and Effect of Variable Renal Function on the Exposure to Aciclovir in Term and Preterm Neonates Wednesday 09:5011:15 
I81 Kim Dao Pharmacokinetic Profile of Sultiame in Healthy Volunteers with In Vitro Characterization of Its Uptake by Red Blood Cells Wednesday 09:5011:15 
I82 Mailys De Sousa Mendes Transporter inhibition: modelling invitro Transwell assays Wednesday 09:5011:15 
I83 Eva Maria del Amo Paez Pharmacokinetics after intravitreal injection of a new antiangiogenic therapeutic compound in rabbit eyes Wednesday 09:5011:15 
I84 Francesca Del Bene Intratympanic drug administration: a challenge for PK modelling Wednesday 09:5011:15 
I85 Laurence Del Frari Population modelling and simulations of binimetinib pharmacokinetics in subjects with hepatic impairment to explore optimal dosing regimen using total and unbound binimetinib exposures Wednesday 09:5011:15 
I86 Oleg Demin Jr Investigation of dose response behavior of bispecific Tcell engaging antibodies using quantitative systems pharmacology modeling Wednesday 09:5011:15 
I87 Laure Deyme Optimizing FOLFIRINOX regimen in pancreatic adenocarcinoma using a 5FUPKPD model of neutropenia including GCSF rescue Wednesday 09:5011:15 
I88 Sofie Dhaese The use of optimal experimental design to inform a clinical trial on nonlinearity of piperacillin clearance in critically ill patients. Wednesday 09:5011:15 
I89 Richard Dimelow PK Precision Estimation to support the Design of a Pediatric Study of Belimumab Administered Subcutaneously Wednesday 09:5011:15 